The alvimopan cohort experienced quicker GI-2 recovery ( 5.5 vs 6.8 d ; hazard ratio : 1.8 ; p < 0.0001 ) , shorter mean LOS ( 7.4 vs 10.1 d ; p = 0.0051 ) , and fewer episodes of POI-related morbidity ( 8.4 % vs 29.1 % ; p < 0.001 ) .